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SUMMARY
Although it is well established that tumor-associated
macrophages take part in each step of cancer pro-
gression, less is known about the distinct role of
the so-called metastasis-associated macrophages
(MAMs) at the metastatic site. Previous studies re-
ported that Caveolin-1 (Cav1) has both tumor-pro-
moting and tumor-suppressive functions. However,
the role of Cav1 in bone-marrow-derived cells is
unknown. Here, we describe Cav1 as an anti-meta-
static regulator in mouse models of lung and breast
cancer pulmonary metastasis. Among all the re-
cruited inflammatory cell populations, we show that
MAMs uniquely express abundant levels of Cav1.
Using clodronate depletion of macrophages, we
demonstrate that macrophage Cav1 signaling is
critical for metastasis and not for primary tumor
growth. In particular, Cav1 inhibition does not affect
MAM recruitment to the metastatic site but, in turn,
favors angiogenesis. We describe a mechanism by
which Cav1 in MAMs specifically restrains vascular
endothelial growth factor A/vascular endothelial
growth factor receptor 1 (VEGF-A/VEGFR1) signaling
and its downstream effectors, matrix metallopepti-
dase 9 (MMP9) and colony-stimulating factor 1
(CSF1).
INTRODUCTION
During cancer progression, a heterogeneous population of
bone-marrow-derived cells (BMDCs) is recruited to the primary
tumor site as well as to the pre-metastatic niche or established
metastasis (Joyce and Pollard, 2009). Among all BMDCs,
macrophages represent the most abundant population and the
cells most extensively studied thus far. The plasticity of these
cells has long been recognized, and it is known that macro-
phages carry the potential to not only sustain cancer progression
and immunosuppression but also elicit cytotoxicity and antigen
presentation and thus immune responses against cancer (Alla-
vena et al., 2008). This opposite response is strictly dependent
on the microenvironmental stimuli these cells are subjected to,
which can vary from tumor to tumor and from the different niches
they occupy (Casazza et al., 2013; Henze and Mazzone, 2016).
Although it is now well established that tumor-associated
macrophages (TAMs) take part in each step of cancer growth
(Ruffell and Coussens, 2015), less is known about the distinct
role of so-called metastasis-associated macrophages (MAMs)
at the metastatic site. Several studies have demonstrated
different mechanisms through which MAMs support cancer
malignancy (Hiratsuka et al., 2002; Qian et al., 2015); however,
it is also possible that the immune system induces dormancy
in cancer cells that have extravasated to the metastatic site
and thus blocks their proliferation and growth (Sosa et al.,
2014). Studies in mice using sarcoma, melanoma, and pancre-
atic cancer models have all pointed to CD4+ T cells and/or
CD8+ cytotoxic T cells as the main executors of this metastatic
dormancy (Eyles et al., 2010; Koebel et al., 2007; M€uller-Herme-
link et al., 2008). When looking at the involvement of innate
immunity in this process, little is known about the ability of
neutrophils and macrophages at the metastatic site to prevent
the dissemination or growth of cancer cells (Granot et al.,
2011; Lo´pez-Lago et al., 2013).
Here, we describe how Caveolin-1 (Cav1) in MAMs prevents
metastatic growth in the E0771 orthotopic breast cancer model,
the subcutaneous Lewis lung carcinoma (LLC) model and the
genetically engineered polyomamiddle T (MMTV-PyMT) sponta-
neous breast cancer model. Cav1 is the major component of en-
docytic caveolae plasma membrane invaginations, and as such,
it can control the turnover and activity of several proteins and
signaling pathways, such as endothelin B, epidermal growth
factor receptor (EGFR), insulin-like growth factor receptor 1
(IGFR-l), and transforming growth factor b (TGF-b) (Couet
et al., 1997; He et al., 2015; Ravid et al., 2005; Yamaguchi
et al., 2003). In general, Cav1 has been reported to have both
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tumor-promoting and tumor-suppressive functions, being pro-
or anti-survival depending on the cancer cell type (Felicetti
et al., 2009; Sunaga et al., 2004; Tanase et al., 2009; Witkiewicz
et al., 2010). It is thus clear that the Janus properties of Cav1 are
likely due to cell-specific effects, physiological context, and can-
cer stage. In addition, Cav1 has been characterized in some cell
populations of the tumor stroma, where it also shows contrasting
effects. For example, in tumor endothelial cells, the expression of
Cav1 has been reported to modulate angiogenesis and vascular
permeability both positively and negatively (Gratton et al., 2003;
Lin et al., 2007; Morais et al., 2012). In cancer-associated fibro-
blasts, Cav1 underlines matrix stiffness and favors tumor inva-
sion and metastasis (Goetz et al., 2011), whereas others have
shown that its loss in fibroblasts correlates with poor prognosis
(Capozza et al., 2012; Simpkins et al., 2012). However, the role
of Cav1 in BMDCs, particularly macrophages, was never
disclosed.
Usingchimericmice,whichareCav1wild-type (WT)orknockout
(KO) in the bonemarrow compartment, we describe here a mech-
anism by which Cav1 in MAMs restrains vascular endothelial
growth factor A/vascular endothelial growth factor receptor 1
(VEGF-A/VEGFR1) signaling and its downstream effectors, matrix
metallopeptidase 9 (MMP9) and colony-stimulating factor 1
(CSF1). Gene targeting of Cav1 in MAMs unleashes VEGFR1+
MAMs and MMP9 activity, which in turn favors the angiogenic
switch and metastatic growth. With this in mind, we define here
an anti-metastatic function of Cav1 in macrophages.
RESULTS
Deletion of Cav1 in BMDCs Leads to Increased
Metastasis in Multiple Tumor Models
In order to investigate the role ofCav1 inBMDCs,we transplanted
bone marrow (BM) from WT or Cav1 KO mice into lethally irradi-
ated WT recipient mice, WT/WT and Cav1 KO/WT, respec-
tively. Upon reconstitution, Cav1 KO/WT chimeras displayed
normal blood counts comparable to those of WT/WTmice (Ta-
ble S1). We then implanted LLC cells subcutaneously. Although
primary tumor growth and weight were not different between
both groups of chimeric mice (Figures 1A and S1A), Cav1 KO/
WTchimerashad2-foldmore lungmetastases thanWT/WTchi-
meras (Figures 1B and 1C). Histologically, the total metastatic
area was increased upon bone marrow Cav1 deletion, as well
as the average size of individual lungmetastasis (Figures 1D–1F).
In an alternative tumor model, which was obtained by injecting
E0771 breast cancer cells orthotopically in themammary fat pad,
lung metastases were significantly increased upon deletion of
Cav1 in the BM, whereas primary tumor growth was similar
between groups (Figures 1G, 1H, and S1B). Histological quanti-
fications showed a drastic increase in the average size of individ-
ual lung metastasis in Cav1 KO/WT chimeras as compared to
WT/WTmice (Figures 1I and 1J). In order to further confirm the
anti-metastatic role of Cav1 in BMDCs, we used the polyoma
middle T (MMTV-PyMT) spontaneous breast cancer mouse
model, which resembles the characteristics of human luminal
breast cancer (Lin et al., 2003). Consistent with our previous
models, we transplanted the BM from WT or Cav1 KO mice in
12-week-old lethally irradiated PyMT recipient mice (8 weeks
before the first tumor onset). We observed that BMCav1 deletion
in these mice did not affect PyMT primary tumor growth or
weight (Figures 1K and S1C). However, the number of metastatic
nodules in the lung was much higher in Cav1 KO/WT PyMT
chimeras than in WT/WT PyMT controls (Figure 1L). Histolog-
ical quantifications showed that the total metastatic area, as
well as the average size of individual lung metastases, was
also increased in PyMT mice upon BM Cav1 deletion (Figures
1M–1O). Together, these data suggest that Cav1 in BMDCs
has an anti-metastatic function in the lungs without affecting pri-
mary tumor growth at other sites.
Macrophages Are Responsible for IncreasedMetastasis
in Cav1 KO/WT Chimeras
In tumor-bearing mice, MAMs isolated from lung metastases
displayed the highest levels of Cav1 expression in comparison
to TAMs or other immune cells sorted from either the primary
tumor or pulmonary metastasis (Figure 2A). Prompted by these
data, we evaluated whether Cav1 in macrophages played a
role during metastatic growth. Using clodronate liposomes, we
achieved an !55%–60% reduction in macrophage infiltration
at the primary tumor and metastatic sites (Figure S2). In this
setting, the difference in metastasis between WT/WT and
Cav1 KO/WT chimeras was completely abrogated (Figure 2D).
At the level of the primary site, clodronate-liposome treatment
caused equal tumor growth and weight reduction in both
WT/WT and Cav1 KO/WT chimeras (Figures 2B and 2C).
However, both TAM and MAM infiltration was not affected by
Cav1 deficiency (Figures 2E, 2F, S2A, and S2B). Overall, these
data suggest that Cav1 deletion in macrophages is responsible
for increased metastasis.
The Pro-metastatic Function of Cav1 KO Macrophages
Is Likely Restricted to the Lungs
Interestingly, when measuring the expression of Cav1 in different
tissues of healthy mice, we found that only CD45+CD11b+F4/80+
Figure 1. Deletion of Cav1 in BMDCs Leads to Increased Metastasis in Multiple Tumor Models
(A–F) LLC tumor growth (A) of lethally irradiatedWTmice reconstituted withWT (WT/WT) or Cav1 KO (Cav1 KO/WT) BM cells. Quantification of the number of
lung metastatic nodules (B) and representative images (C). Metastatic nodules are indicated by arrows. Histological analysis of lung metastasis showing the total
metastatic area per mouse (D), average size of each metastasis (E), and representative mosaic images of H&E stained lung sections (F). Scale bar, 2 mm. n = 30
mice per genotype.
(G–J) Tumor growth (G) and number of lung metastatic nodules (H) in an orthotopic E0771 breast cancer model. Histological analysis of lung metastasis showing
the average size of each metastasis (I) and representative mosaic images of H&E stained lung sections (J). Scale bar, 2 mm. n = 8 mice per genotype.
(K–O) Total tumor growth (K) and number of lung metastatic nodules (L) of lethally irradiated PyMT mice reconstituted with WT or Cav1 KO BM cells. Histological
analysis of lung metastasis showing the total metastatic area per mouse (M), the average size of each metastasis (N), and representative mosaic images of H&E
stained lung sections (O). Scale bar, 2 mm. n = 7 mice per genotype.
*p < 0.05, **p < 0.01, and ***p < 0.001 versus WT/WT. All graphs show mean ± SEM.
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interstitial macrophages in the lungs, but not hepatic or bone-
marrow-resident macrophages, displayed abundant Cav1
expression levels (Figure 3A). Fu et al. (2012) previously showed
thatmonocytes treated for 7 dayswithCSF2 (also knownas gran-
ulocyte-macrophage colony-stimulating factor [GM-CSF]) dis-
played increasedexpression levelsofCav1. Consistentwith these
findings,weobserved that 7 days ofCSF2 treatment could induce
high Cav1 expression levels in both blood- and spleen-derived
Ly-6C+F4/80low/"Ly6G" monocytes (Figure 3B). Downregulation
of Ly6c1 and upregulation of Erm1 expression upon treatment
with CSF2 supports the differentiation of monocytes into macro-
phages (Figure 3C). These data suggest that upon monocyte
arrival to the lungs and during their transition into macrophages,
Cav1 expression can be induced by CSF2, a factor known to
play a key role in thehomeostatic control of the pulmonarymacro-
phage phenotype (Kopf et al., 2015; Lavin et al., 2015; Mantovani
andAllavena, 2015). Basedon theseobservations,we then tested
whether theorgancontextplaysa role in theobservedphenotype.
For this, we examined breast cancer metastasis to the liver by
performing portal vein injection of E0771 breast cancer cells
(Goddard et al., 2016). After 10 days, we detected no difference
in the number of metastatic nodules in the liver between Cav1
KO/WT chimeras and WT/WT mice (Figures 3D–3F). Alto-
gether, we conclude that the effects of Cav1 deletion in MAMs
are likely restricted to the lung parenchyma.
Cav1 Deletion in MAMs Leads to Increased Metastatic
Growth and Angiogenesis
Because we observed that MAMs show much higher Cav1
expression than TAMs (Figure 2A), we hypothesized that the
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Figure 2. Macrophages Are Responsible for Increased Metastasis in Cav1 KO/WT Chimeras
(A) Cav1 expression in CD45+CD11b" non-myeloid cells, CD45+CD11b+F4/80+ macrophages (TAMs), CD45+CD11b+Ly6G+ neutrophils, and other
CD45+CD11b+Ly6G"F4/80"myeloid cells derived from the primary tumor and CD45+CD11b" non-myeloid cells, CD45+CD11b+F4/80+ macrophages (MAMs),
CD45+CD11b+Ly6G+ neutrophils, and other CD45+CD11b+Ly6G"F4/80"myeloid cells sorted from metastatic nodules of LLC-tumor-bearing mice. n = 4 mice.
(B–D) Tumor growth (B), weight (C), and number of lung metastatic nodules (D) in LLC-tumor-bearing mice treated with macrophage-depleting clodronate
liposomes or PBS. n = 11 mice per genotype.
(E and F) F4/80+ macrophage accumulation in LLC metastasis (E) and representative images (F). Scale bar, 100 mm. n = 8 mice per genotype.
xp < 0.05 versus other cell populations, *p < 0.05 versus WT/WT, and #p < 0.05 versus PBS. ns, not significant. All graphs show mean ± SEM.
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effect of Cav1 on metastasis is independent of the primary
tumor. We therefore injected LLC cells directly into the blood-
stream. After 20 days, we found a significantly higher number
of pulmonary metastatic nodules in Cav1 KO/WT versus
WT/WT mice (Figure 4A). While Cav1 deletion in KO/WT chi-
meras positively affected metastatic cancer cell growth at a late
stage, their extravasation and lodging in the early stage after
intravenous cancer cell injection was not affected (Figure 4B).
We can therefore argue that Cav1 KO macrophages represent
supportive MAMs, which mediate the escape from tumor cell
dormancy and increase tumor cell proliferation independently
of the primary tumor and initial tumor cell extravasation.
In an attempt to further characterize the phenotype of Cav1 KO
macrophages in the metastatic niche, we evaluated features
of the MAM infiltrate by fluorescence-activated cell sorting
(FACS) and analyzed the expression of the M1-like marker major
histocompatibility complex class II (MHC class II) and theM2-like
marker CD206 (Mrc1) on the cell membrane of F4/80+ cells
(Laoui et al., 2014). The abundance of immune cells in general
and specifically of macrophages in the metastasis was compa-
rable in both groups of chimeric mice (Figures 4C and 4D).
Additionally, Cav1 KO/WT chimeras displayed similar
numbers of MHC class IIlow and CD206high MAMs as compared
to WT/WT controls (Figures 4E and 4F). Additionally,
Cav1 KO/WT chimeras had numbers of metastasis-infiltrating
CD4+ and CD8+ T cells (TCR-b+ cells), neutrophils
(CD11b+Ly6G+ cells), natural killer (NK) cells (NKp46+ cells),
and B cells (CD45R+ cells) similar to WT/WT mice (Figure S3).
Gene expression markers typically used to characterize the
classically (M1-like) and alternatively activated (M2-like) macro-
phage phenotype were also unaltered in MAMs derived from
WT/WT and Cav1 KO/WT chimeras (Figure S4), suggesting
that deletion of Cav1 does not affect macrophage polarization.
During our attempt to understand the biological reasons un-
derlying the metastatic boost upon hematopoietic deletion of
Cav1, we found that vessel density in the metastatic lesion
A B
C
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Figure 3. The Pro-metastatic Function of Cav1 KO Macrophages Is Likely Restricted to the Lungs
(A) Cav1 expression in CD45+CD11b+F4/80+ macrophages (MQ) sorted from bone, liver, and lung tissue of healthy mice. n = 10 mice.
(B and C) Cav1 expression in blood- and spleen-derived monocytes treated for 7 days with GM-CSF (CSF2) or vehicle (B), and expression of Ly6C1 and Emr1 at
day 7 in spleen-derived monocytes (C). n = 4 mice.
(D–F) Number of liver metastatic nodules upon portal vein injection of E0771 cells (D). Histological analysis of hepatic metastasis showing the average size of each
metastasis (E)andrepresentativemosaic imagesofH&Estained liver sections (F).Metastaticnodulesare indicatedbyarrows.Scalebar, 2mm.n=5micepergenotype.
*p < 0.05, **p < 0.01, and ***p < 0.001 versus vehicle. ns, not significant. All graphs show mean ± SEM.
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was markedly augmented in Cav1 KO/WT versus WT/WT
chimeras (Figures 4G and 4H). However, blood vessel density
in LLC primary tumors was comparable in both groups of
chimeric mice (Figure 4I). The enhanced angiogenesis at the
metastatic site in Cav1 KO/WT mice was completely pre-
vented by clodronate-liposome treatment (Figure 4J). Impor-
tantly, the observed angiogenic phenotype was consistent in
our spontaneous breast cancer model and was organ specific,
because PyMT lung metastases in Cav1 KO/WT chimeric
mice showed increased blood vessel density, whereas experi-
mental liver metastases did not (Figures 4K–4N).
We also studied the functionality and vascular integrity of the
blood vessels in the pulmonary metastases. However, blood
vessels in Cav1 KO/WT metastatic lesions did not show any
differences in normalization and permeability as compared to
WT/WT mice in terms of hypoxic area, pericyte coverage,
and number of leaked red blood cells in the perivascular space
(Figures S5A–S5C). In addition, the perivascular localization of
macrophages in the pulmonary metastatic lesions did not
display any significant differences between WT/WT and
Cav1 KO/WT mice (Figure S5D). Altogether, these data
suggest that MAM-associated Cav1 negatively regulates the
sprouting of new blood vessels (but not their function), and this
occurs specifically at the lung metastatic site, where Cav1 is
abundantly expressed by interstitial macrophages.
Augmented VEGFR1 Activity upon Cav1 Deletion in
Macrophages Leads to Increased MMP9-Mediated
Metastatic Growth and Angiogenesis
Caveolae are important structural elements involved in modu-
lating signal transduction of several receptors such as VEGFR1,
CCR2, or others depending on the cell context (Casalou et al.,
2011; Catusse et al., 2009; Dzenko et al., 2001; Fu et al., 2012;
Ge and Pachter, 2004). In order to elucidate the mechanism by
which Cav1 deletion leads to increased blood vessel formation,
we investigated which cell surface receptors on MAMs are
modulated by Cav1. Interestingly, upon Cav1 deletion, macro-
phages sorted from metastatic nodules showed increased
protein expression of VEGFR1 (also known as Flt1) at the
membrane surface (Figure 5A), whereas Vegfr1 transcripts
were the same in both WT and Cav1 KO MAMs (Figure S6A).
The upregulation of VEGFR1 in Cav1 KO MAMs was specific,
because other cell surface receptors were unaltered (Figures
S6B–S6D). Augmented VEGFR1 expression was found only in
MAMs, because protein levels of VEGFR1 were similar in
WT/WT and Cav1 KO/WT TAMs (Figure 5A). Moreover, we
showed that VEGFR1 modulation by Cav1 was responsible for
the observed phenotype, because treating mice with the
VEGFR1-blocking antibody MF1 abrogated the increased
metastatic growth and vessel formation in Cav1 KO/WT chi-
meras intravenously injected with LLC cells (Figures 5B
and 5C). Previous studies have shown that VEGFR1 activity
drives Mmp9 expression in the context of cancer (Bergers
et al., 2000; Hiratsuka et al., 2002; Li et al., 2015). Accordingly,
we observed a strong increase in Mmp9 expression in macro-
phages uponCav1 deletion, which was inhibited after MF1 treat-
ment (Figure 5D). In addition, by using an inhibitor of MMP9, we
rescued metastatic growth in Cav1 KO/WT mice down to the
same levels observed in WT/WT mice (Figure 5E). Accompa-
nying the expression data on Mmp9, we observed increased
MMP9 activity in sortedMAMs upon deletion of Cav1 (Figure 5F).
Because VEGF-A is the most prominent angiogenic factor
secreted by MAMs that stimulates vascular permeability and
tumor cell extravasation, we tested the relevance of this ligand
in Cav1 KO macrophages (Qian et al., 2011a). We showed that
both Vegfa expression and secretion of VEGF-A in MAMs were
unaffected upon deletion of Cav1 (Figures 5G and 5H). To rule
out the possibility that other MMP9-mediated capabilities be-
sides angiogenesis are required for the increased formation of
metastasis in Cav1 KO/WT mice, we blocked angiogenesis
by injecting DC101 antibodies that, by recognizing VEGFR2,
specifically target endothelial cells, but not macrophages
(Koch and Claesson-Welsh, 2012). At day 20 upon LLC tail
vein injection, DC101 treatment in Cav1 KO/WT chimeras
abrogated the increased metastatic growth and angiogenesis
to the same levels as control-treated WT/WT mice (Figures
5I–5K), confirming that vessel formation is responsible for the
observed phenotype.
Enhanced VEGF-A/VEGFR1 Signaling upon Cav1
Deletion in MAMs Leads to Downstream Activation of
the CSF1/MMP9 Axis
VEGF-A and placental growth factor (PlGF) are the two VEGFR1
ligands involved in angiogenesis (Fischer et al., 2008). Of these
two ligands, we found that LLC and E0771 cancer cells express
high levels of Vegfa but barely detectable levels of Plgf (Fig-
ure 6A). Similar results were obtained when quantifying the
amount of Vegfa and Plgf in LLC-derived lung lesions in WT
mice (Figure 6A). Therefore, we decided to block only the
VEGF-A ligand and assess how this affects the expression of
MMP9. For this approach, WT/WT and Cav1 KO/WT mice
were consecutively treated with VEGF-A-blocking antibodies
Figure 4. Cav1 Deletion in MAMs Leads to Increased Metastatic Growth and Angiogenesis
(A) Number of lung metastatic nodules upon tail vein injection of LLC cells. Total mice, n = 6 per genotype.
(B) Tumor cell extravasation measured by qRT-PCR analysis on whole lungs upon tail vein injection of LLC cells. Total mice, n = 4 per condition.
(C–F) FACS quantification of total CD45+ leukocytes (C), F4/80+ MAMs (D), M2-like CD206+ MAMs (E), and MHC class IIlow MAMs (F) in WT/WT and Cav1
KO/WT lung metastatic lesions. n = 4 mice per genotype.
(G–I) Number of CD31+ blood vessels in LLC metastatic lesions (G) and representative images (H). Scale bar, 50 mm. Number of CD31+ blood vessels in primary
LLC tumors (I). n = 10 mice per genotype.
(J) Number of CD31+ blood vessels in LLC metastatic lesions upon treatment with clodronate liposomes or PBS. n = 9 mice per condition.
(K and L) Number of CD31+ blood vessels in lung metastatic lesions of PyMT mice (K) and representative images (L). Scale bar, 50 mm. Total mice, n = 7 per
genotype.
(M and N) Number of CD31+ blood vessels in E0771 metastatic lesions in the liver (M) and representative images (N). Scale bar, 50 mm. n = 5 mice per genotype.
**p < 0.01, ***p < 0.001, and ****p < 0.0001 versus WT/WT. #p < 0.05 versus PBS. ns, not significant. All graphs show mean ± SEM.
2848 Cell Reports 21, 2842–2854, December 5, 2017
A B C
ED F
J
IHG
K
Figure 5. Augmented VEGFR1 Activity upon Cav1 Deletion in Macrophages Leads to Increased MMP9-Mediated Metastatic Growth and
Angiogenesis
(A) FACS analysis of the mean VEGFR1 signal intensity on CD45+CD11b+F4/80+ macrophages in LLC primary tumors (TAMs) or metastatic lesions (MAMs).
n = 4 mice per genotype.
(B–D) Number of lung metastatic nodules upon tail vein injection of LLC cells in mice treated with VEGFR1-blocking antibodies (MF1) or control IgG (Ctrl IgG) (B),
and number of CD105+ blood vessels in metastatic lesions (C). Mmp9 gene expression in FACS-sorted CD45+CD11b+F4/80+ MAMs from mice treated with
VEGFR1-blocking antibodies (MF1) or control IgG (Ctrl IgG) (D). Total mice, n = 5 per genotype.
(legend continued on next page)
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at day 16 and 18 upon LLC tail vein injection. Anti-VEGF-A anti-
bodies were able to rescue metastatic growth in Cav1 KO/WT
mice to the same levels observed in WT/WT mice (Figure 6B).
Moreover, Mmp9 expression in Cav1 KO MAMs treated with
anti-VEGF-A decreased to the same levels observed in WT
MAMs (Figure 6C), suggesting that VEGFR1-MMP9 signaling
upon Cav1 deletion in MAMs is mainly driven by the VEGF-A
ligand.
Qian et al. (2015) have previously shown that CSF1 (also
known as macrophage colony-stimulating factor [M-CSF]) is a
downstream gene target of VEGFR1 in MAMs. We therefore
tested the expression of CSF1 in Cav1 KO MAMs and found
that Cav1 KOMAMs display significantly higher Csf1 expression
levels than WT MAMs (Figure 6D). Moreover, MF1 treatment
leads to a strong abrogation of Csf1 expression levels in Cav1
KO MAMs (Figure 6D), suggesting a possible involvement of
CSF1 in the Cav1 KO macrophage phenotype. Furthermore,
Qian et al. (2015) also showed that macrophage recruitment to
the lung was unaffected by MF1 inhibition. We further demon-
strated that MAM recruitment was indeed unaffected in either
immunoglobulin G (IgG)-treated and MF1-treated Cav1 KO/
WT chimeras (Figure 6E).
In conclusion, these data argue that increased VEGF-
A/VEGFR1 activity upon Cav1 deletion in MAMs drives the
downstream expression of MMP9 and CSF1, altogether facili-
tating blood vessel formation and metastatic growth in the lungs
(Figure 6F).
DISCUSSION
Although many studies have thoroughly characterized the role of
TAMs and their plastic phenotypes at the primary tumor, far less
is known about MAMs in the metastatic niche. Previous studies
have shown that circulating monocytes are recruited to the lung
metastatic niche and release VEGF that permeabilizes blood
vessels, thus enforcing breast cancer cell extravasation (Qian
et al., 2011a). Once in the lung parenchyma, metastatic breast
cancer cells receive survival signals from MAMs through the
interaction of vascular cell adhesion molecule-1 (VCAM-1) and
a4-integrins (Chen et al., 2011). Moreover, macrophage VEGFR1
expression, while dispensable for MAM recruitment, is determi-
nant for the regulation of a set of prometastatic genes in MAMs,
such asCsf1 in breast cancer lung metastases (Qian et al., 2015)
or Mmp9 in B16 or LLC lung metastases (Hiratsuka et al., 2002;
Kaplan et al., 2005).
In contrast to these metastasis-promoting activities, our data
highlight an intrinsic anti-metastatic surveillance mechanism
whereby upregulation of Cav1 in MAMs controls excessive
expression of VEGFR1, thus limiting expression of MMP9 and
CSF1, angiogenesis, and metastatic growth (Figure 6F). These
effects are limited to the metastatic niche and were not
observed in the primary tumor, possibly because of two rea-
sons. First, MAMs show a much higher expression of Cav1
than TAMs. This might be induced by the lung microenviron-
ment, in which high Cav1 expression is important to orchestrate
appropriate innate immune reactions to pathogens and aller-
gens (Jin et al., 2011). Second, persistent hypoxia (present in
the primary tumor) is known to strongly upregulate VEGFR1
expression (Eubank et al., 2011; Okuyama et al., 2006; Roda
et al., 2011), thereby possibly saturating any modulatory effects
by low Cav1 expression levels in TAMs. Indeed, hypoxic tumor
areas are characterized by the presence of VEGFR1high macro-
phages that actively secrete MMP9 and thus promote angio-
genesis and invasion (Du et al., 2008). Based on our data, we
suggest a model in which a VEGFR1-MMP9 signaling axis in
lung MAMs is rapidly quenched by high Cav1 expression,
because the treatment of metastasis-bearing mice with the
anti-VEGFR1 antibody MF1 did not result in a reduction of
Mmp9 gene expression. On the other hand, KO of Cav1
increased the membrane exposure of VEGFR1 on MAMs, re-
sulting in increased transcription and activity of MMP9, overall
inducing excessive blood vessel formation and expanded
metastatic size. Nevertheless, a further decrease in lung
metastases in WT/WT mice upon MMP9 inhibitor treatment
was also observed, which can be explained by the inhibition
of MMP9 derived from other cell types, such as endothelial
cells (Hiratsuka et al., 2002).
Recent data published by Qian et al. (2015) has demonstrated
thatMAMs uniquely express VEGFR1 at the cell surface, which is
critical for spontaneous lungmetastasis, via downstream regula-
tion of a set of inflammatory genes. Among these genes, Csf1, a
key factor for macrophage survival, was shown to be the main
target gene, promoting metastatic growth once cancer cells
seed into the lungs. In an effort to link this closely related study
with our observed phenotype, we discovered that Cav1 KO
MAMs display higher expression levels of Csf1 than WT
MAMs, which were abrogated upon MF1 treatment. These
data could indicate that Cav1 deletion in MAMs could boost
the CSF1 inflammatory cascade through excessive exposure
of VEGFR1 at the cell surface. Previous studies have shown
that blockage of VEGFR1 and CSF1 signaling leads to inhibition
of MMP9-mediated actions and consequently suppression of
metastatic growth (Kaplan et al., 2005; Priceman et al., 2010).
However, further studies are warranted to unravel whether
MMP9 and CSF1 act either as two epistatic processes or as
one cascade where Mmp9 expression is downstream CSF1
signaling. When seeking the VEGFR1 ligands responsible for
this cascade, we found that VEGF-A, but not placental growth
(E) Number of lung metastatic nodules upon tail vein injection of LLC cells in mice treated with MMP9 inhibitor or vehicle. n = 7 mice per condition.
(F) MMP9 activity in FACS-sorted CD45+CD11b+F4/80+ MAMs measured by gelatin zymography. n = 5 mice per genotype.
(G and H) Vegfa gene expression in FACS-sorted CD45+CD11b+F4/80+ MAMs from WT/WT and Cav1 KO/WT chimeras (G). Protein levels of VEGF-A,
measured by ELISA, in the cell supernatants of FACS-sorted CD45+CD11b+F4/80+ MAMs from WT/WT and Cav1 KO/WT chimeras (H). n = 4 mice per
genotype.
(I–K) Number of lung metastatic nodules upon tail vein injection of LLC cells in mice treated with VEGFR2-blocking antibodies (DC101) or vehicle (I), number of
CD105+ blood vessels in lung metastatic lesions (J), and representative images (K). Scale bar, 50 mm. n = 6 mice per condition.
*p < 0.05, **p < 0.01, and ****p < 0.0001 versus WT/WT. #p < 0.05 versus Ctrl IgG or vehicle. ns, not significant. All graphs show mean ± SEM.
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Figure 6. Enhanced VEGF-A/VEGFR1 Signaling upon Cav1 Deletion in MAMs Leads to Downstream Activation of the CSF1/MMP9 Axis
(A) Vegfa and Plgf expression in E0771 and LLC cancer cells in culture (in vitro), and expression of these genes in LLC-derived metastatic lesions (in vivo).
n = 4 mice.
(B and C) Number of lung metastatic nodules upon tail vein injection of LLC cells in mice treated with anti-VEGF-A antibodies (anti-VEGF) or control IgG (Ctrl IgG)
(B) and Mmp9 gene expression in FACS-sorted CD45+CD11b+F4/80+ MAMs (C). n = 4 mice per condition.
(D and E) Csf1 gene expression in FACS-sorted CD45+CD11b+F4/80+ MAMs from mice treated with VEGFR1-blocking antibodies (MF1) or control IgG (Ctrl IgG)
(D), and FACS quantification of total F4/80+ MAMs (E). n = 5 mice per condition.
(F) Schematic overview of the data showing that deletion of Caveolin-1 (Cav1) in metastasis-associated macrophages (MAMs) drives VEGF-A/VEGFR1 activity
and its downstream effectors, MMP9 and CSF1, which in turn favors the angiogenic switch and metastatic growth. Wild-type (WT) MAMs control the excessive
exposure of VEGFR1 at the membrane surface via Cav1-mediated internalization, leading to a decrease in the levels ofMmp9 andCsf1 transcripts, which results
in inhibition of metastatic growth and angiogenesis.
*p < 0.05 versus WT/WT. #p < 0.05 versus Ctrl IgG. All graphs show mean ± SEM.
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factor (PIGF), was expressed both in vivo and in vitro, at least in
our tumor models. Together with this finding, the use of VEGF-A-
blocking antibodies supports the idea that VEGFR1-MMP9
signaling upon Cav1 deletion in MAMs is mainly driven by
VEGF-A.
In the attempt to further characterize the mechanism of Cav1
signaling, we observed that monocytes, treated for 7 days with
CSF2 (GM-CSF), display significantly higher Cav1 expression
levels when differentiated into mature macrophages. These
data suggest that CSF2 can induce high Cav1 expression
levels in monocyte-derived macrophage subsets, such as
interstitial macrophages in the lung. In this context, we can
hypothesize that CSF2 might block VEGFR1-CSF1 signaling
in a Cav1-dependent manner and thus suppress MMP9-CSF1
pro-metastatic signaling. These data are in agreement with
previously proposed competition models between the actions
of CSF1 and CSF2 (Fleetwood et al., 2007; Hamilton, 2008).
However, further in vivo experiments are required to support
the validity of this concept.
Another important aspect of this study relates to the organ
specificity of the observed phenotype, meaning that the effects
of Cav1 deletion in MAMs are limited to the lung parenchyma
as compared to other metastatic sites, such as the liver. We
showed that, upon portal vein injection of E0771 breast cancer
cells, metastatic growth and vessel density of liver metastatic
lesions was unaffected upon BM deletion of Cav1. In addition,
the use of subcutaneous LLCs, orthotopic E0771, and transgenic
PyMT breast tumors, which all developed larger spontaneous
lungmetastasis inCav1KO/WTmice, allowsus to further spec-
ulate on the results obtained upon intravenous injection of LLC
cells, which also showed enhanced metastatic growth in Cav1
KO/WTmice. Because the latter is a model of lung cancer cells
colonizing the pulmonary tissue, previous work has referred to
this approach as an orthotopic model of primary lung tumor
growth (Goto et al., 2002; Moncho-Amor et al., 2011; Ottewell
et al., 2006). Therefore, it is licit to think that Cav1 inmacrophages
might play a suppressive role during both primary lung carcino-
genesis and lung metastasis. However, in vivo models of lung
carcinogenesis are required to validate this hypothesis.
In conclusion, the role of Cav1 has been extensively studied in
cancer, with a focus on cancer cells, endothelial cells, and fibro-
blasts, leading to the suggestion that the Caveolin scaffolding
domain can be used in the treatment of cancer (Gratton et al.,
2003; Simpkins et al., 2012; Williams et al., 2004). The thera-
peutic administration of Cav1 scaffold protein might be a worth-
while pursuit, because the loss of Cav1 in the tumor stroma has
been previously associated with more aggressive disease and
poor patient outcomes in breast cancer, pancreatic cancer,
and melanoma (Jia et al., 2014; Qian et al., 2011b; Wu et al.,
2011). We complemented these observations by studying the
role of Cav1 in immune cells and thus disclosed an anti-metasta-
tic protective function of Cav1 that is exclusive to MAMs, but not
other immune compartments.
EXPERIMENTAL PROCEDURES
More detailed methods can be found in Supplemental Experimental
Procedures.
Animals
Cav1 KO mice on a C57BL/6 background were obtained from Dr. Feron (UC
Louvain, Brussels, Belgium). C57BL/6 mice were purchased from Charles
River Laboratories. All mice used were between 5 and 13 weeks old,
without specific gender selection. In all experiments, littermate controls
were used. Housing and all experimental animal procedures were approved
by the Institutional Animal Care and Research Advisory Committee of KU
Leuven.
BM Transplantation
6-week-old C56BL/6 recipient mice were lethally irradiated with 9.5 Gy.
Subsequently, 103 106 BM cells from the appropriate genotype were injected
intravenously via tail vein. Tumor experiments were initiated 6–8 weeks after
BM reconstitution. Blood cell count was determined using a hemocytometer
on peripheral blood collected by retro-orbital bleeding.
Tumor Models
1 3 106 LLC cells were injected subcutaneously or 5 3 105 E0771 cells
were injected orthotopically in the mammary fat pad. Tumor volumes
were measured three times a week with a caliper using the formula
V = p 3 d2 3 D/6, where d is the minor tumor axis and D is the major tumor
axis. At the end stage, tumor weight was measured and lung metastasis
nodules were contrasted after intratracheal injection of 15% India ink
solution or by H&E staining on lung paraffin sections. Superficial metastatic
nodules were assessed under a stereomicroscope. Macrophage depletion
was achieved by intraperitoneal (i.p.) injection of a loading dose of 250 mL
clodronate and control PBS liposomes (ClodronateLiposomes, the
Netherlands). 12 hr later, LLC tumor cells were injected subcutaneously
followed by another dose of 250 mL liposomes 6 hr after injection. During
tumor progression, repeated injections of 250 mL were performed every
second day to prevent repopulation of macrophages. MMTV-PyMT sponta-
neous breast tumors were measured 20 weeks after birth (8 weeks after
BM transplantation), twice a week with a caliper, and mice were killed at
week 25.
LLC Lung Colonization Experiments
5 3 105 LLC cells in 200 mL PBS were injected directly in the bloodstream.
VEGFR1 inhibition was achieved by i.p. injection of 20 mg/kg mouse
anti-VEGFR1 antibodies (clone MF1, Thrombogenics) or isotype IgG control
(Sigma-Aldrich) every second day. MMP9 inhibition was achieved by daily
gavage injection of 15 mg/kg MMP9 inhibitor II (444293, Millipore), previously
diluted in 50% methylcellulose. DC101 treatment was achieved by i.p. injec-
tion of 40 mg/kg rat anti-mouse VEGFR2 antibodies (BioXCell) twice a week.
Blockage of VEGF-A was achieved by i.p. injection of 40 mg/kg chimeric
anti-mouse VEGF-A (clone B20, ThromboGenics) or isotype IgG control
(Sigma-Aldrich). Anti-VEGF injections were performed at day 16 and 18
upon LLC tail vein injection, and mice were killed at day 20.
FACS Analysis and Flow Sorting of Tumor- and Metastasis-
Associated Macrophages
Tumor-bearing mice were sacrificed by cervical dislocation, and tumors
and macroscopic lung metastasis were harvested. Tumors and metastases
were minced in RPMI medium containing 0.1% collagenase type I and 0.2%
dispase type I and incubated in the same solution for 30 min at 37#C.
The myeloid cell population in the tumor single-cell suspension was stained
for CD45, CD11b, and the pan-macrophage marker F4/80. Cells were
subsequently washed and resuspended in FACS buffer before FACS
analysis or flow sorting by a FACS Verse or FACS Aria III (BD Biosciences),
respectively.
Statistical Analysis
Data entry and all analyses were performed in a blinded fashion. All statistical
analyses were performed using GraphPad Prism software. Statistical signifi-
cance was calculated by two-tailed unpaired t test on two experimental
conditions or two-way ANOVA when repeated measures were compared,
with p < 0.05 considered statistically significant. All graphs show mean ±
SEM values.
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